WORCESTER, Mass.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (Advanced Cell, ACT) (OTCBB: ACTC) announced today that its Chief Executive Officer, William Caldwell, IV, presented at the BIO Europe Conference being held in Vienna, Austria. The presentation provided a corporate overview and update on the Company’s plans for its clinical pathway in addition to several other upcoming developmental milestones, including its planned IND filing with the FDA for its retinal pigment epithelial (RPE) program prior to the end of this year, and its goal of becoming one of the first companies to treat a patient with an embryonic stem cell based therapy, which it hopes to achieve by the third quarter of 2010. Pending FDA approval, ACT hopes to commence Phase I clinical trials for its first IND designation in the summer of 2010, and anticipates filing an IND for an additional retinal indication in a similar timeframe.
